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Abstract
Chlorophyllin (CHL) is a promising chemopreventive agent believed to block cancer primarily by
inhibiting carcinogen uptake through the formation of molecular complexes with the carcinogens.
However, recent studies suggest that CHL may have additional biological effects particularly when
given after the period of carcinogen treatment. This study examines the post-initiation effects of
CHL towards aflatoxin B1 (AFB1)-induced preneoplastic foci of the liver and colon. The single
concentration of CHL tested in this study (0.1% in the drinking water) had no significant effects on
AFB1-induced foci of the liver and colons of rats.
Background
During the past decade chlorophyllin (CHL) has pro-
gressed from initial in vitro anti-mutagenicity experiments
to in vivo studies of anti-tumor mechanisms in trout, mice,
and rats [reviewed by [1]], and into successful chemopre-
vention trials in humans exposed to dietary aflatoxin B1
(AFB1) [2]. An important mechanism for the protective
effects of CHL as a blocking agent appears to be the ability
of this planar compound to complex with carcinogens,
thus preventing carcinogen-DNA adduction. However,
several recent studies focusing on post-initiation effects of
CHL suggest that CHL may have additional effects inde-
pendent of molecular complex formation. In one report,
CHL caused a concentration dependent suppression of
liver tumor formation in rats treated with the heterocyclic
amine, 2-amino-3-methylimidazo [4,5-f]quinoline (IQ)
[3]. In that study, CHL treatment was started 1 week after
the last dose of carcinogen, suggesting that CHL might be
effective as a suppressing agent in the liver. Although CHL
suppressed IQ-induced liver carcinogenesis in the rat, del-
eterious effects have been reported in the colon, including
tumor promotion in some studies [3,4]. These additional
biological properties of CHL could possibly be mediated
through effects on apoptosis [5] or drug metabolism [6-
8].
In the present study, we examined the post-initiation
effects of CHL towards AFB1-induced putative preneoplas-
tic foci of the liver and colon.
Methods
Animals
Male F344 rats, 3 weeks of age were purchased from the
National Cancer Institute (Frederick, MD) and housed
two per cage in shoebox cages at 22° on a 12 hr light/dark
cycle. All rats were fed AIN-93G diet (Dyets Inc., Bethle-
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ham, PA) ad libitum. Prior to and during the period of car-
cinogen administration, the diet was free of ethoxyquin
since this antioxidant prevents the formation of putative
preneoplastic foci in rat livers [9]. Cardboard tubes were
provided for environmental enrichment. Rats were
weighed weekly throughout the experiment.
Chemicals
CHL was a gift from Dr. T.W. Kensler and was lot-matched
to the CHL preparation used in the human clinical trial
[2]. AFB1 was obtained from Aldrich (Milwaukee, WI). All
other chemicals were obtained from Sigma-Aldrich (St.
Louis, MO).
Experimental design
Following a two-week acclimation to antioxidant free
AIN-93G diet, rats were randomly assigned to one of 4
treatment groups as shown in figure 1. Rats were given tri-
octanoin (groups 1 and 2) or 250 µg/kg AFB1 in triocta-
noin (groups 3 and 4) five times per week for two weeks
by oral gavage. Beginning one week after the last AFB1 gav-
age, and continuing for 12 weeks, groups 2 and 4 were
given 0.1% CHL in their drinking water. Fresh CHL solu-
tions were prepared and administered every other day.
After 12 weeks of CHL treatment rats were euthanized
with carbon dioxide and livers and colons removed.
Quantification of GST-P positive hepatic foci
Livers were sliced into multiple 3 mm sections, fixed in
acetone, and processed for histology using the AmesX fix-
ation and processing procedure [10]. Slides were stained
for expression of GST-P and examined by light micros-
copy as previously described [11]. The volume percent of
liver occupied by GST-P positive foci is considered the
least biased and most analogous to tumor burden [12];
therefore, this was the primary endpoint evaluated.
Quantification of colonic ACF
Colons were removed, washed with chilled phosphate
buffered saline, fixed mucosa side up in 10% phosphate
buffered formalin, stained with 0.2% methylene blue, and
ACF scored as previously described [13]. All samples were
coded so that the individual analyzing them was blinded
to the treatment group and animal numbers.
Statistical analysis
Results are expressed as means ± S.D. within a treatment
group. Data were evaluated by analysis of variance
(ANOVA) with post-hoc Tukey's and Bonferroni multiple
comparison tests. Analyses were performed using the SAS
or StatView statistical packages (SAS Institute, Cary, NC).
Results
Rats treated with AFB1 had significantly lower growth rates
than vehicle-treated animals; however, there were no sig-
nificant differences in growth rates (Fig. 2) or food or liq-
uid consumption (not shown) between the water and
CHL-treated rats.
GST-P positive foci were seldom observed in vehicle-
treated rats (0.07 foci/cm2 liver examined); but were com-
mon in AFB1-treated rats (11 foci/cm2) (Fig. 3A). Twelve
weeks of post-initiation treatment with 0.1% CHL had no
significant effects on AFB1-induced GST-P positive focal
density (Fig. 3A) or volume percent of liver occupied with
GST-P positive foci (Fig. 3B).
The AFB1 treatment regime utilized in this study resulted
in aberrant crypt foci (ACF) in colons of 80% of AFB1-
Effects of CHL and AFB1 on body weights Figure 2
Effects of CHL and AFB1 on body weights. Data are mean (± 
SE) at each timepoint.
Experimental protocol for evaluation of the effects of post- initiation CHL on the development of hepatic GST-P positive  foci and colonic ACF Figure 1
Experimental protocol for evaluation of the effects of post-
initiation CHL on the development of hepatic GST-P positive 
foci and colonic ACF. Rats received 250 µg AFB1 per kg body 
weight five times a week for two weeks. Beginning one week 
after the end of the initiation period and continuing for 12 
weeks, half of the animals were given 0.1% CHL in their 
drinking water.Journal of Carcinogenesis 2006, 5:6 http://www.carcinogenesis.com/content/5/1/6
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treated rats (Examples are shown in Figure 4). These puta-
tive preneoplastic foci were not found in the colons of
vehicle-treated animals. Post-initiation treatment with
0.1% CHL had no significant effect on the incidence, mul-
tiplicity, or size of ACF (Figure 4A–C).
Discussion/conclusion
CHL is a promising chemopreventive agent that is
believed to block the bioavailability of certain carcinogens
by forming complexes with the carcinogen. CHL is a
highly effective blocking agent in animal models and was
recently shown to be effective at reducing urinary afla-
toxin-DNA adduct biomarkers in humans exposed to high
levels of dietary aflatoxins [2]. In addition to the well-
established carcinogen blocking mechanism of CHL,
some studies suggest that CHL may have additional bio-
logical properties. The dose-dependent suppression of IQ-
induced liver tumor formation by CHL [3] raises the excit-
ing possibility that the benefit of CHL towards hepatocar-
cinogenesis could be even greater than predicted by
reductions in DNA adduct formation. However, the
mixed results of CHL towards colon carcinogenesis
[3,4,14] suggest that under certain circumstances CHL
may have detrimental effects.
Although AFB1 is primarily considered a liver carcinogen,
lifetime exposure also produces colon tumors in rats, par-
ticularly in vitamin A deficient animals [15-17]. Based on
two case reports of aggressive colon cancer in humans
occupationally exposed to aflatoxins [18] and the pres-
ence of AFB1 DNA-adducts in colorectal cancer tissue from
patients in the United Kingdom [19], the colon may also
be a target organ of AFB1 carcinogenesis, particularly in
parts of the world where hepatitis B infection is uncom-
mon. Although the primary purpose of this study was to
examine the post-initiation effects of CHL on preneoplas-
tic foci of the liver, this experiment also provided an
opportunity to determine if the AFB1 exposure protocol
routinely used to produce altered hepatic foci in rats also
results in preneoplastic lesions of the colon. Indeed, this
AFB1 exposure produces a high incidence and multiplicity
of ACF and provides a unique opportunity to simultane-
ously examine the effects of chemopreventive agents on
preneoplastic foci of both the liver and colon.
Hepatic GST-P positive foci and colonic ACF are well-
established markers for estimating the effect of chemopre-
ventive agents on tumor outcome. GST-P positive foci
accurately predicted the protective effects of oltipraz
towards AFB1-induced hepatocarcinogenesis [20] and the
potency of over 60 chemopreventive agents at inhibiting
ACF correlates extremely well with their effects on tumor
formation [21].
However, the process of tumor development is complex
and our understanding of which preneoplastic markers
will progress to tumors is incomplete. Recently the role of
ACF as precancerous lesions has been challenged by stud-
ies suggesting that mucin depleted foci [22,23], beta-cat-
enin accumulated crypts [24,25], or other atypical foci
[26] may be of greater value at predicting tumor forma-
tion than the typical ACF first described by Bird in 1987
[27]. While the strong correlation between ACF and color-
ectal cancer in laboratory animals [21] and their presence
in humans at risk for colorectal cancer [28-30] continue to
support the utility of these foci for predicting tumor out-
come, we recognize that no preneoplastic markers can
fully replace tumors as the ultimate endpoint. Therefore,
additional studies examining the post-initiation effects of
CHL towards AFB1-initiated liver and colon cancer may be
appropriate as the use of this chemopreventive agent
becomes more widespread. However, the current study
suggests that post-initiation treatment with 0.1% CHL is
unlikely to modulate liver or colon tumor formation
based on the lack of effects towards the formation of
AFB1-induced hepatic GST-P positive foci and colonic
ACF.
Effects of CHL and AFB1 on liver GST-P positive foci Figure 3
Effects of CHL and AFB1 on liver GST-P positive foci. Data 
are mean (± SE) for each treatment group. (A) No. Foci per 
cm2. (B) Volume percent of liver occupied by foci.Journal of Carcinogenesis 2006, 5:6 http://www.carcinogenesis.com/content/5/1/6
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Effects of CHL and AFB1 on colonic ACF Figure 4
Effects of CHL and AFB1 on colonic ACF. Data are mean (± SE) for each treatment group. (A) Incidence (% of animals with 
ACF). (B) Number of ACF per colon. (C) Size (# crypts) of ACF. Insert photos show examples of foci containing (A) two, (B) 
four, and (C) seven aberrant crypts.Journal of Carcinogenesis 2006, 5:6 http://www.carcinogenesis.com/content/5/1/6
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A major limitation of this study is that only a single con-
centration of CHL (0.1%) was tested. This concentration
was selected because 0.1% CHL is the concentration that
is most effective at inhibiting IQ induced liver tumors [3].
However, promotion of DMH-induced colon tumors
occurs at much lower CHL concentrations (0.001%) [3].
Additional studies examining a range of CHL concentra-
tions are necessary before concluding that CHL does not
enhance AFB1-induced colon carcinogenesis. However,
this study demonstrates that the protocol used to examine
effects of chemopreventive agents towards AFB1-induced
altered hepatic foci can include preneoplastic foci of the
colon as an additional endpoint.
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